Damaging effects of advanced glycation end-products in the murine macrophage cell line J774A.1.
The interaction of reducing sugars, such as aldose, with proteins and the subsequent molecular rearrangements, produces irreversible advanced glycation end-products (AGEs), a heterogeneous class of non-enzymatic glycated proteins or lipids. AGEs form cross-links, trap macromolecules and release reactive oxygen intermediates. AGEs are linked to aging, and increase in several related diseases. The aim of this study was to assess, in a murine macrophage cell line, J774A.1, the effects of 48 h of exposure to glycated serum containing a known amount of pentosidine, a well-known AGE found in the plasma and tissues of diabetic and uremic subjects. Fetal bovine serum was incubated with ribose (50 mM) for 7 days at 37 degrees C to obtain about 10 nmol/ml of pentosidine. The cytotoxic parameters studied were cell morphology and viability by neutral red uptake, lactate dehydrogenase release and tetrazolium salt test. In the medium and in the intracellular compartment, bound and free pentosidine were evaluated by HPLC, as sensitive and specific glycative markers, and thiobarbituric acid reactive substances (TBARs), as index of the extent of lipid peroxidation. Our results confirm that macrophages are able to take up pentosidine. It is conceivable that bound pentosidine is degraded and free pentosidine is released inside the cell and then into the medium. The AGE increase in the medium was combined with an increase in TBARs, meaning that an oxidative stress occurred; marked cytotoxic effects were observed, and were followed by the release of free pentosidine and TBARs into the culture medium.
Bassi
A M
AM
Department of Experimental Medicine, Section of General Pathology, University of Genoa, Via L.B. Alberti, 2, I-16132, Genoa, Italy. ambassi@medicina.unige.it
Ledda
S
S
Valentini
S
S
De Pascale
M C
MC
Rossi
S
S
Odetti
P
P
Cottalasso
D
D
D000818:Animals; D001120:Arginine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D003920:Diabetes Mellitus / Q000503:physiopathology; D017127:Glycation End Products, Advanced / Q000009:adverse effects*; D015227:Lipid Peroxidation; D008239:Lysine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008264:Macrophages / Q000473:pathology*; D051379:Mice; D018384:Oxidative Stress; D012266:Ribose / Q000378:metabolism*
D017127:Glycation End Products, Advanced; D012266:Ribose; D001120:Arginine; C062187:pentosidine; D008239:Lysine